Life Sciences DNA Podcast – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

Life Sciences DNA Podcast

Levine Media Group

Sciences

Business & Entrepreneuriat

Fréquence : 1 épisode/18j. Total Éps: 49

The Life Sciences D’n’A podcast is hosted by AI and data analytics experts and pharma industry veterans Nagaraja Srivatsan and Amar Drawid. They explore the evolving use of AI and data science with innovators working to reshape all aspects of the biopharmaceutical industry from the way new therapeutics are discovered to how they are marketed.

Lire plusRéduire

Site

RSS

Apple

Données mises à jour le 04/07/2026

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

🇺🇸 États-Unis - Life Sciences
27/08/2026
#88
🇬🇧 Grande Bretagne - Life Sciences
09/06/2026
#99
🇬🇧 Grande Bretagne - Life Sciences
08/06/2026
#84
🇬🇧 Grande Bretagne - Life Sciences
07/06/2026
#68
🇬🇧 Grande Bretagne - Life Sciences
05/06/2026
#43
🇬🇧 Grande Bretagne - Life Sciences
04/06/2026
#26
🇬🇧 Grande Bretagne - Life Sciences
03/06/2026
#78
🇬🇧 Grande Bretagne - Life Sciences
02/06/2026
#70
🇬🇧 Grande Bretagne - Life Sciences
01/06/2026
#60
🇬🇧 Grande Bretagne - Life Sciences
31/05/2026
#44

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://cloud.google.com/resources/content/roi-of-ai-healthcare-life-sciences
2 partages

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 37%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

Human Accountability in an Agentic Pharma World

Épisode 51

jeudi 28 mai 2026 • Durée 49:05

Vertex senior director Amrit Moola sits down with Srivatsan Nagaraja to discuss what it takes to operationalize AI in pharma and biotech from early experiments to large‑scale transformation. He describes how to pick high‑impact use cases, re‑architect processes around agents and real‑time data, and align business operations on outcomes. The discussion ranges from CRO recruitment data and batch disposition in cell and gene therapy to guardrails, governance, and why you can’t blame the algorithm when something goes wrong.

Lire plusRéduire

Making AI Transformations that Stick

Épisode 50

jeudi 14 mai 2026 • Durée 53:11

Vikram Nair, chief information officer of Amneal Pharmaceuticals, joins Srivatsan Nagaraja to break down what it really takes to turn AI from boardroom buzz into real business impact. From early missteps and skeptical stakeholders to building smarter metrics, Nair shares lessons from the front lines of AI transformation—and introduces a practical control framework to help life sciences companies scale AI, manage risk, and evolve without losing control.

Lire plusRéduire

Finding ROI from AI in the Mundane

Épisode 48

jeudi 9 avril 2026 • Durée 46:18

Dennis Salotti, executive director and head of clinical outsourcing and innovation at Jazz Pharmaceuticals, joins Srivatsan Nagaraja to talk about what AI really looks like in day-to-inside a drug company. He explains how large language models and agentic tools can streamline contracting, budgeting, and risk management—mundane but high-impact work that speeds studies and improves trial-site experience. Salotti shares how to design narrow, high‑ROI pilots, build AI fluency, avoid “AI slop,” and turn AI into a thinking partner rather than a shortcut, stacking small wins that remove grunt work, capture lessons learned, and elevate people from doers to critical thinkers.

Lire plusRéduire

A Pragmatic Path to AI-Enabled Commercial Operations

Épisode 47

jeudi 26 mars 2026 • Durée 36:41

Tris Pharma Chief Commercial Officer Manesh Naidu sits down with Nagaraja Srivatsan to discuss how the small but growing specialty pharma company is pursuing a deliberately incremental AI strategy, focusing on its biggest pain points rather than chasing grand, enterprise-wide transformations. He explains how the team is using off-the-shelf and vendor tools where possible, rigorously managing data and compliance risk, and letting quick wins in discrete use cases pave the way for broader change. Naidu discusses what practical AI adoption looks like for Tris, how the company is applying the technology to high-value commercial challenges, and how it is reinventing sales training through virtual physician simulations.

Lire plusRéduire

Reimagining Scientific Work in the Age of AI Agents

Épisode 46

jeudi 12 mars 2026 • Durée 47:28

Shweta Maniar, global strategy and market leader for life sciences at Google Cloud, sits down with Nagaraja Srivatsan to unpack what it takes to turn AI pilots into durable, enterprise-wide impact. A former biotech executive who now helps biopharma leaders modernize their data and AI strategy, Shweta argues that success starts with fixing fragmented data foundations and reshaping culture—not just deploying the latest model. She explains why AI should be treated as a strategic upgrade to de-risk science rather than a narrow tool for squeezing efficiency, why the hardest problems are less about model performance and more about data and organizational behavior, and how emerging multi-agent systems could compress timelines from discovery to patient access. You can download The ROI of AI in Healthcare and Life Sciences report referenced in the discussion here: https://cloud.google.com/resources/content/roi-of-ai-healthcare-life-sciences

Lire plusRéduire

Orchestrating Scientists, Data, and AI to Discover New Drugs

Épisode 45

jeudi 26 février 2026 • Durée 46:11

Scotch McClure had a bold plan for Maxwell Biosciences to map and mine the roughly 3 percent of peptides circulating in human plasma. The company has harnessed AI to move from a massive and messy universe of human peptides to a small-molecule candidate that could offer a potential alternative to antibiotics, antifungals, and some antivirals. McClure, CEO of Maxwell, sat down with Nagaraja Srivatsan to discuss why he thinks AI is becoming the central engine that makes modern drug development not just faster but possible at all, how he sees AI as essential to filtering out the noise in vast datasets, and why organizations will need to surrender more of the scientific process to AI while constraining it with a clear vision and guardrails.

Lire plusRéduire

Scaling Practical AI Across Commercial Teams

Épisode 44

jeudi 12 février 2026 • Durée 48:55

Drew McCormick, head of data and analytics at Eversana, sits down with Nagaraja Srivatsan to trace the company’s AI journey from classic predictive modeling in its data and analytics business to an enterprise-wide strategy. He describes how Eversana is building on a strong data foundation to tackle challenges such as patient identification, while also rethinking workflows, governance, and talent to ensure AI delivers value in a highly regulated environment.

Lire plusRéduire

Building an AI-Ready Biopharma Organization

Épisode 42

jeudi 8 janvier 2026 • Durée 54:51

Scott Cenci, chief information and data officer for Acadia Pharmaceuticals, sits down with Nagaraja Srivatsan to discuss how generative and agentic AI are reshaping biopharma throughout the enterprise from R&D and clinical development to the commercial field. He discusses how it is changing the roles of people like medical writers into medical editors, why every knowledge worker will soon manage AI agents as part of their job; and the hard problems leaders face in prioritizing AI investments, avoiding experiment fatigue, governing enterprise data, and building a culture of continuous learning.

Lire plusRéduire

Automating Biopharma Workflows with AI and Robotics

Épisode 41

mercredi 24 décembre 2025 • Durée 37:48

Karthik Raman, co-founder and CEO of Persist AI, sits down with the Nagaraja Srivatsan to discuss how robotics, AI, and cloud tech are supercharging drug formulation to address a bottleneck in pharma R&D. He explains how robots outperform humans in consistency and scale, igniting a flywheel of faster prototyping, richer data, and AI-orchestrated workflows that will propel biopharma innovation amid rising drug complexity.

Lire plusRéduire

De-Risking Discovery and Improving the Success Rates of Drug Development with AI

Épisode 40

jeudi 11 décembre 2025 • Durée 42:03

Gabi Tarcic, vice president of product for Evogene, sits down with Srivatsan Nagaraja about applying AI to small molecule drug discovery, the cultural and operational changes required for researchers to adopt these tools, and how AI-driven platforms can improve the efficiency of pharma R&D.

Lire plusRéduire

Podcasts et contenus similaires

Autres podcasts ou contenus associés partageant des thèmes ou audiences similaires.

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à Life Sciences DNA Podcast. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !

Il n'y a pas de contenu associé à ce podcast.

À propos Méthodologie Contact Me soutenir Politique de confidentialité Mentions légales

Life Sciences DNA Podcast – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

Cloud Provider1

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts et contenus similaires

Podcasts Similaires Basées sur le Contenu

Podcasts Similaires Basées sur le Contenu

Cloud Provider1

Apple Podcasts

Spotify